Tissue factor pathway inhibitor

Minerva Medica

Volumn 90, Issue 1-2, 1999, Pages 25-32

  Camici, M ^b,c   Sagripanti, A ^a  

^a Department of Internal Medicine ^*  (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Blood coagulation physiology; Thromboplastin; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ATHEROSCLEROSIS; BLOOD CLOTTING; ENDOTOXEMIA; REVIEW; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; LIPOPROTEINS;

EID: 0032984912     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Weiss HJ, Lages B. Evidence for tissue factor dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988;71:629-35
2. Callander LS, Varki N, Rao LVM Immunohistochemical identification of tissue factor in solid tumors Cancer 1992;70:1194-201.
3. Wilcox JN, Smith KM, Schwartz SM, Gordon D Localization of tissue factor in the normal vessel all and in the atherosclerotic plague. Proc Natl Acad Sci USA 1989;86.2839-43.
4. Rivers RPA, Hathway WE, Weston WI. The endotoxin induced coagulant activity of human monocytes. Br J Haemathol 1975;30:311-6
5. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein associated coagulation inhibitor the inhibits factor Xa insight into its possible mechanism of action. Blood 1988;71:335-43.
6. Lindhal AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor Blood Coagul Fibrinolysis 1992,3:439-49.
7. Bojaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocyte do not synthesize-lipoprotein associated coagulation inhibitor: evidence that the endothelium is the principal site of its synthesis Proc Natl Acad Sci USA 1990;87:8869-73.
8. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1980;72:2020-5.
9. Novotny WF, Palmier M, Wun TC, Spoze GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein associated coagulation inhibitor. Blood 1991;78.394-400.
10. Broze GJ, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag Fibrinolysis 1994;5:551-9
11. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated type inhibitory domains. J Biol Chem 1988,263:6001-4.
12. Warner CB, Rao LV, Maki SL, Rapaport SI. Modification f extrinsic pathway inhibitory (EPI) factor Xa that affect their ability to interact and to inhibit factor VIIa: tissue factor. Evidence for a two-step model of inhibition Thromb Haemost 1988;60.453-6.
13. Enjvoti K, Miyata T, Kamikubo Y, Kato H Effect of heparin on the inhibition f factor Xa by tissue factor pathway inhibitor: a segment Gly 212-Phe 243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995;34:5725-35.
14. Warshanski I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95:1773-81
15. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze G Jr. Tissue factor pathway inhibitor the carb, xy-ter i, us is required for optimal inhibition of factor Xa Blood 1992,79.200-10
16. Sandset PM, Warm CB, Rao LV, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascufar coagulation induced with tissue factor: evidence supporting a physiological role for EPI as natural anticoagulant. Proc Natl Acad Sci USA 1991,88 708-12
17. Sandset PM, Warm CB, Maki SL, Rapaport SI Immunodepletion of extrinsic pathway inhibitor sensitizes rabbit to endotoxin-induced intravascular coagulation and the general Schwartzman reaction Blood 1991,78 1496-502.
18. Warr TA, Rao LV, Rapaport SI Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990,75.1481-9.
19. Novotny WF, Brown SG, Miletich JP, Rader DL, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patients samples. Blood 1991,78:387-93.
20. Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagulat Fibrinol 1993;4.699-706
21. Warm CB, Alnus FE, Rapaport SI. Studies of the factor Xa-dependent inhibitor of factor VIIa: tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothehal cells. Thromb Haemost 1989,11 101-5
22. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993;69:366-9.
23. Enjyoji KI, Emi E, Mukai T, Jmada M, Leppert M, Lalouel JM et al Human tissue factor pathway inhibitor (TFPI) gene: complete genomic structure and localization on the genomic map of chromosome 2q. Genomics 1993;17:423-8.
24. Palmier MO, Holl LJ, Reisch CM, Baldwing MK, Wilson AG, Wun TG Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992;68 33-6.
25. Bregengaard C, Nordfang O, Ostergaard P, Petersen JGL, Meyen G, Diness V et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993;70:454-7.
26. Kounas MZ, Argraves WS, Strickland DK. The 39-KDa-receptor-associated protein interacts with two members of the low density lipoprotein receptor family, α 2 macroglobulin receptor and glycoprotein 330. J Biol Chem 1992;267:21162-6.
27. Warshawski I, Broze GJ Jr, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994,91:6664-8.
28. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989;109:389-95.
29. Callander NS, Rao LV, Nordfang O, Sandset PM, Warm CB, Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces, evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 1992,267:876-82.
30. Rapaport SI, Rao LVM. The tissue factor pathway how it has become a "prima ballerina". Thromb Haemost 1995,747-17
31. Broze GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995,74 90-3.
32. Cole ES, Nichols EH, Hamois LM, Livingstone DJ. In vivo clearance of tissue plasminogen activator: the complex role of glycosylation and level of sialyation. Fibrinolysis 1993,7:7-15.
33. Lindhout T, Frausseu G, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor Thromb Haemost 1995;74/3:910-5.
34. Huang ZF, Wun TC, Broze GJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993;268-26950-5.
35. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies LDL and HDL and with Lp(a). Arter Thromb 1993;13:1066-75.
36. Hansen JB, Huseby NE, Sandset PM, Swensson B, Lyngmo V, Nordoy A. Tissue factor pathway inhibitor and lipoproteins Arter Thromb 1994;14:223-9.
37. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor, from human plasma. J Biol Chem 1989;264.18832-7.
38. Warm-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa dependent plasma inhibitor) of factor VIIa/tissue factor. Thromb Res 1987,48.11-22.
39. Valentine S, Nordfang O, Bregenguard C, Wildgoose P Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo i tercation with lipoproteins Blood Coagul Fibrinol 1993,4.713-20.
40. Novonty WF Tissue factor pathway inhibitor. Sem Thromb Hemost 1994;20 101-8.
41. Wun TC, Huang MD, Kretzmer KK. Immuno-affinity purification and characterization of LACI from HepG2 hepatoma. Chang liver, and SK hepatoma cells. J Biol Chem 1990;265:16096-101.
42. Sandset PM, Abildgaard LI, Larsen ML Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
43. Hubbard AR, Weller LJ, Gray E Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinol 1994;5:819-23.
44. Maoori A, Connard J, Samama MM. Tissue factor pathway inhibitor (TFPI) during prolonged treatments by unfractionated (UH) or low molecular weight heparin (LMWH). Thromb Haemost (Abstract) 1993; 69:681.
45. Iversen N, Sandset PM, Abildgaard U, Rao V, Nordfang O. Binding of recombinant tissue factor pathway inhibitor (rTFPI) to endothelial cells, influence of glycosaminoglycans Thromb Haemost (Abstract) 1993; 69:644.
46. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection, increased response in cancer patients Thromb Res 1990,59:651-6.
47. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post heparin plasma and- in plasma from cancer patients Blood Coagul Fibrin 1991;2:713-21.
48. Valentin S, Lamkjaer A, Osatergaard P, Nilsen JI. Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994;75:173-83.
49. Novotny WF, Day KC, Wun TC, Nicees G. Platelet LACI is present in novel granules. Blood 1990,76:4699.
50. Valentin S, Wildgoose P, Bregengaard C, Nordfang O. Tissue factor pathway inhibitor: the importance of the C-terminus for its in vitro and in vivo interaction with lipoprotein. Abstract Thromb Haemost 1993;68:499
51. Hubbard AR, Weller LJ. Detection of tissue factor pathway inhibitor in normal and post-heparin plasma by functional and immunological techniques. Thromb Haemost (Abstract) 1993,69:502.
52. Moor E, Hamstem A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994;71:707-12.
53. Wildgoose P, Valentin S, Nordfang O. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its interaction with lipoproteins. Thromb Haemost 1991;65:768.
54. Broze GJ Jr, Wesselschmidt R, Higuchi D, Girard T, Likert K, Macphail L, Wun TC. The interaction between LACI and heparin. Adv Exp Med Biol 1993;313 189.
55. Wesselschmidt R, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactively with factor Xa and heparin. Blood 1992;80: 2639.
56. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothehal cells. J Biol Chem 1992;267:20435-433.
57. Wun TC Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin synergistic anticoagulant action between LACI and sulfated polysaccharides Blood 1992;79 430-8.
58. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res 1993,69:443-52.
59. Kristensen HI, Ostergaard PB, Nordfang O, Abildgaard U, Linadhl AK. Effect of tissue factor pathway inhibitor (TFPI) in the heptest assay and in an amidolytic anti factor Xa assay for LMW heparin Thromb Haemost 1992;69:310-4
60. Ostergaard P, Nordfang O, Petersen LC, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Haemostasis 1993,23(Suppl 1):107-11.
61. Jeske W, Hoppensteadt D, Callas D, Koza MJ, Fareed J. Pharmacological profiling of recombinant tissue factor pathway inhibitor. Sem Thromb Haemost 1996;22/2:213-9
62. Khuori R, Koudsi B, Omberg R, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plastic Surg 1993;30:398-404.
63. Cade JF, Buchanan MR, Boneu B, Ockelford PA A comparison of the antithrombotic and hemorrhagic effects f low molecular eight heparin fractions and the influence of preparation. Thromb Res 1984.35:613-25.
64. Goodwin CA, Melissani E, Kakkar VV, Scully MF. Plasma levels of tissue factor pathway inhibitor in thrombophilic patients. Thromb Res 1993;72:363-6
65. Tollefsen D. Heparin: basic and clinical pharmacology. In: Hoffman, R, Benz, E, Shattil S, Furie B, Cohen H, editors. Hematology: basic principles and practice. New York: Churchill Livingstone, 1991:257-74
66. Basic-Micic M, Roman C, Herbel U, Kling E, Scholz B, Breddin K. Platelet-induced thrombin generation time: a new sensitive global assay for platelet function and coagulation. Methods and results. Haemostasis 1992,22: 309-21.
67. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982,60: 1353-8.
68. Repke D, Gemmell GH, Guha A, Turitto VT, Broze GJ Jr. Hemophilia as a defect of the tissue factor pathway of coagulation: effect of factors VII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990;87:7623-7.
69. Holst J, Lindblad B, Bergvist D, Nordfang O, Ostergaard PB, Petresen JG et al Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI 1-161) in experimental venous thrombosis a comparison with low molecular weight heparin. Thromb Haemost 1994,71 214-9.
70. Day KC, Spokas E, Broze GJ Jr, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation in the rabbit Blood 1990;76:1538-45
71. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock J Clin Invest 1993,91:2850-6.
72. Oltrana L, Speidel CM, Recchia D, Abendschein DR. Inhibition of tissue factor-mediated thrombosis markedly attenuates stenosis after balloon-induced arterial injury in hyperlipidemic minipigs. Circulation 1994;90:1-344
73. Llobet D, Falkon L, Mateo J, Vallve C, Martine E, Fontcuberta J et al. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophiha Thromb Res 1995;80/5:413-8.